Astrazeneca PLC Company Profile (NYSE:AZN)

Analyst Ratings

Consensus Ratings for Astrazeneca PLC (NYSE:AZN) (?)
Ratings Breakdown: 2 Sell Rating(s), 9 Hold Rating(s), 10 Buy Rating(s), 1 Strong Buy Rating(s)
Consensus Rating:Hold (Score: 2.45)
Consensus Price Target: $36.67 (6.93% upside)

Analysts' Ratings History for Astrazeneca PLC (NYSE:AZN)
Show:
DateFirmActionRatingPrice TargetActions
7/28/2016Cantor FitzgeraldReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/27/2016Shore CapitalReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/27/2016Citigroup Inc.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/19/2016Beaufort SecuritiesReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/18/2016Bank of America Corp.Reiterated RatingBuy$36.65View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016ArgusInitiated CoverageHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/27/2016Deutsche Bank AGReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/16/2016Leerink SwannReiterated RatingHold$34.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/6/2016Jefferies GroupReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016JPMorgan Chase & Co.Reiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/27/2016Goldman Sachs Group Inc.Reiterated RatingSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/28/2016Drexel HamiltonInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/8/2016HSBCDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/5/2016Sanford C. BernsteinLower Price Target$34.00 -> $32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/26/2016Oddo SecuritiesUpgradeNeutral -> Top PickView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/19/2016Barclays PLCUpgradeUnderweight -> Equal Weight$44.00 -> $50.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/13/2016Credit Suisse Group AGReiterated RatingUnderperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/30/2015Morgan StanleyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/30/2015BNP ParibasReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/2/2015Nordea Equity ResearchDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/18/2015Bryan, Garnier & CoUpgradeNeutral -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/31/2015S&P Equity ResearchUpgradeBuy$38.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/31/2015SwedbankUpgradeNeutral -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/2/2015Berenberg BankUpgradeHold -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2015Kepler Capital MarketsReiterated RatingReduceView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/16/2015Liberum CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/15/2015Societe GeneraleInitiated CoverageBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/6/2015Panmure GordonReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/6/2015DanskeDowngradeSellView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/3/2015SEB Equity ResearchUpgradeHold -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2014 forward)

Earnings

Earnings History for Astrazeneca PLC (NYSE:AZN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
7/28/2016Q216$0.76$0.83$5.56 billion$5.60 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/29/2016Q1$0.60$0.51$5.96 billion$6.12 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/4/2016Q415$0.88$0.94$6.27 billion$6.40 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315$0.51$1.03$5.90 billion$5.85 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/30/2015Q2$1.08$1.21$6.02 billion$5.84 billionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/24/2015Q1$1.07$1.08$5.87 billion$6.06 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/5/2015Q314$0.85$0.76$6.68 billion$6.68 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q3$1.04$1.05$6.44 billion$6.54 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2014Q214$1.09$1.30$6.24 billion$6.45 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/24/2014Q114$1.23$1.17$6.32 billion$6.42 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/6/2014Q413$1.22$1.23$6.91 billion$3.84 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2013Q313$1.27$1.21$6.45 billion$6.25 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2013Q213$1.16$1.20$6.24 billion$6.23 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/25/2013$1.36$1.41$6.54 billion$6.39 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
1/31/2013Q412$1.37$1.56$7.17 billion$7.28 billionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/25/2012$1.44$1.51ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/26/2012$1.38$1.53ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/26/2012$1.73$1.81ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/2/2012$1.57$1.61ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/27/2011$1.64$1.71ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/28/2011$1.74$1.53ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Astrazeneca PLC (NYSE:AZN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$0.53$1.01$0.77
Q2 20162$0.40$0.45$0.43
Q3 20161$0.55$0.55$0.55
Q4 20161$0.58$0.58$0.58
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Astrazeneca PLC (NYSE:AZN)
Annual Dividend:$1.37
Dividend Yield:4.00%
Payout Ratio:59.57% (Based on Trailing 12 Months of Earnings)
68.16% (Based on Current Year Consensus EPS Estimate)
71.35% (Based on Next Year Consensus EPS Estimate)
Dividend Growth:-6.60% (3 Year Average)

Dividend History for Astrazeneca PLC (NYSE:AZN)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable DateShare
2/5/2016$0.932/17/20162/19/20163/21/2016Tweet This Announcement  Share This Announcement on StockTwits
2/10/2015semiannual$1.905.57%2/18/20152/20/20153/23/2015Tweet This Announcement  Share This Announcement on StockTwits
8/1/2014semiannual$0.902.48%8/13/20148/15/20149/15/2014Tweet This Announcement  Share This Announcement on StockTwits
2/10/2014special$1.902.79%2/19/20142/21/20143/24/2014Tweet This Announcement  Share This Announcement on StockTwits
8/2/2013semiannual$0.903.52%8/14/20138/16/20139/16/2013Tweet This Announcement  Share This Announcement on StockTwits
2/1/2013special$1.903.72%2/13/20132/15/20133/18/2013Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Astrazeneca PLC (NYSE:AZN)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Astrazeneca PLC (NYSE:AZN)
DateHeadline
07/28/16 03:46 PMAnalyst Recommendations Review: AstraZeneca PLC (NYSE:AZN) - News Oracle
07/28/16 01:13 PMAstraZeneca (AZN) Stock Up After Q2 Earnings, Revenue Beat -
07/27/16 11:14 AMNotable Analysts Recommendation to Monitor: Astrazeneca PLC ... - Street Updates
07/27/16 10:05 AMBristol-Myers Squibb’s 2Q16 Estimates: Other Segments -
07/26/16 08:43 PMA look at a High Market Cap Stock: AstraZeneca PLC, AZN – The ... - The Daily Leicester
07/25/16 03:16 PMAstrazeneca : 2Q 2016 -- Forecast
07/25/16 07:31 AMLatest Analysts Score of Stocks: Astrazeneca PLC (NYSE:AZN) , Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) - Street Updates
07/24/16 10:48 AM[$$] New drugs aim to kill cancer cells by destabilising their DNA - [at Financial Times] - Drugs that selectively destroy cancer cells by destabilising their DNA will be developed in a £6m project funded by the Wellcome Trust at the University of Sussex, in collaboration with AstraZeneca. The ...
07/23/16 02:42 PMAre Analysts Bearish AstraZeneca plc (LON:AZN) After Last Week? - Consumer Eagle
07/22/16 11:58 AMEuropean Stock Markets Mixed After Signs of Brexit Damage -
07/22/16 10:54 AMTrending Stock Analysis: AstraZeneca PLC (NYSE:AZN) - News Oracle
07/22/16 01:05 AM3 post-Brexit picks I’d buy now -
07/21/16 08:16 PMBig Pharma Dominates Healthcare But Caregivers Are Top Sector Yield Dogs In July
07/21/16 08:16 PMAstraZeneca PLC (LON:AZN) stock price target held steady at 4,800GBX as issued in a report today by JP Morgan Cazenove
07/21/16 08:16 PMAstraZeneca Plc (NYSE:AZN) Gets European Commission Approval For Qtern
07/21/16 02:42 PMAstraZeneca Plc (NYSE:AZN) Gets European Commission Approval For Qtern - Market Exclusive
07/21/16 11:25 AMRelypsa Getting Acquired By Swiss Partner Seeking U.S. Entry -
07/21/16 09:58 AMHere’s what Neil Woodford has been buying and selling since the Brexit vote -
07/20/16 10:09 PMWorth Watching Stocks News Recap: AstraZeneca plc (ADR)(NYSE:AZN), Vodafone Group Plc (ADR)(NASDAQ:VOD) - NYSE Journal (press release)
07/20/16 10:09 PMAstraZeneca PLC (LON:AZN) “Hold” Rating Reconfirmed by Analysts at Beaufort Securities - Press Telegraph
07/19/16 10:48 AM11:48 am AstraZeneca enters strategic collaboration with Canada's Centre for Drug Research and Development -
07/19/16 08:53 AMColgate-Palmolive Company (NYSE:CL) & AstraZeneca plc (NYSE:AZN) News Recap - Money News (press release)
07/19/16 08:53 AMAstraZeneca plc (AZN) Pops on Upbeat Drug Data - Schaeffers Research (blog)
07/18/16 02:46 PMAstraZeneca: Tagrisso Met Primary Goal In Phase III 2nd-Line Lung Cancer Trial
07/18/16 02:46 PMAstraZeneca's Tagrisso meets endpoint in trial
07/18/16 02:46 PMAstraZeneca plc (AZN) Pops on Upbeat Drug Data
07/18/16 02:46 PMAstraZeneca PLC (LON:AZN) target price maintained at 4,000GBX as recorded today by Credit Suisse
07/18/16 10:00 AMSoftBank to buy UK chip designer ARM in $32 bln cash deal - [Reuters - UK Focus] - TOKYO/LONDON, July 18 (Reuters) - Japan's SoftBank will buy Britain's most valuable technology company ARM for $32 billion in cash, an audacious attempt to lead the next wave of digital innovation with a chip designer that powers the global mobile phone industry. Led by the charismatic Japanese investor, Masayoshi Son, SoftBank swooped on the Apple supplier ARM in the three weeks since Britain voted to leave the European Union, a result which stunned financial markets and has sent sterling down 11 percent against both the dollar and yen.
07/18/16 07:36 AMShares of Astrazeneca PLC (AZN) Rally 0.43% - TheFounders Daily
07/18/16 06:22 AMAstraZeneca lung cancer drug meets late-stage trial endpoint -
07/18/16 06:12 AMTAGRISSO® (OSIMERTINIB) Met Primary Endpoint in Phase III 2nd-Line Lung Cancer Trial - [Business Wire] - AstraZeneca today announced that the AURA3 Phase III trial met its primary endpoint, demonstrating superior progression-free survival compared to standard platinum-based doublet chemotherapy.
07/15/16 07:00 PMStocks Trending Alert: Activision Blizzard, Inc. (ATVI), AstraZeneca PLC (AZN), Lloyds Banking Group plc (LYG) - iStreetWire
07/15/16 07:00 PMEye Catching Stock for investors: AstraZeneca PLC (NYSE:AZN) - News Oracle
07/15/16 07:00 PMShares of Astrazeneca PLC (AZN) Sees Large Outflow of Money - TheFounders Daily
07/14/16 11:38 AMA report released earlier today by Jefferies International about (LON:AZN) AstraZeneca PLC raises the target price to 4,800GBX
07/14/16 11:38 AMJefferies Group Increases AstraZeneca plc (AZN) Price Target to GBX 4800
07/14/16 06:30 AMDon't Wrap a Union Jack Around U.K. Plc -
07/14/16 01:20 AM3 shares Neil Woodford backs despite Brexit ‘sideshow’ -
07/13/16 08:10 PMAstraZeneca Enters Into Deal To Resolve Faslodex Patent Litigation In US
07/13/16 08:10 PMA statement released today by JP Morgan Cazenove about AstraZeneca PLC(LON:AZN) ups the target price to 4,800GBX
07/13/16 02:44 PMEye Catching Stock: AstraZeneca PLC (NYSE:AZN) - News Oracle
07/13/16 10:51 AMLONDON - AstraZeneca PLC (AZN L, AZN) announced Wednesday that it has entered into an agreement with Sandoz, Inc
07/13/16 10:51 AMAstraZeneca, Sandoz reach patent resolution
07/13/16 08:55 AMAstraZeneca (AZN) Stock Advancing on Patent Litigation Resolution -
07/12/16 08:12 PMArgus Concerned With Near-Term Challenges At AstraZeneca
07/12/16 08:12 PMA report released earlier today by Berenberg about AstraZeneca PLC(LON:AZN) ups the target price to 5,400GBX
07/12/16 02:48 PMAstraZeneca plc (NYSE:AZN) considering A $10 Billion Bid For Medivation Inc (NASDAQ:MDVN) - Market Exclusive
07/12/16 02:27 PMAstraZeneca (AZN) Stock Up, Argus Research Initiates Coverage -
07/12/16 01:44 PMWhy Relypsa Stock Is Ripping -
07/02/16 05:44 AMHow Post-Brexit Currency Fluctuations Could Affect U.S. ADR Holders -

Social

About Astrazeneca PLC

Astrazeneca PLC logoAstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas. The Company has its operations in over 100 countries. The Company's pipeline includes over 150 projects of which approximately 125 are in the clinical phase of development. The Company is developing a Toll-like receptor 9 (TLR-9) receptor agonist aimed at producing long-term benefit in asthma by addressing imbalances in the immune system. AstraZeneca offers various products, including Accolate, Rhinocort, Bricanyl Turbuhaler, Rhinocort, Symbicort pMDI, Crestor, Seloken/Toprol-XL, Brilinta/Brilique (ticagrelor), Bydureon, Xigduo XR, Kombiglyze XR and metformin XR, among others.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: AZN
  • CUSIP:
Key Metrics:
  • Previous Close: $34.29
  • 50 Day Moving Average: $29.63
  • 200 Day Moving Average: $29.56
  • P/E Ratio: 29.82
  • P/E Growth: -13.36
  • Market Cap: $86.75B
  • Beta: 0.71
  • Current Year EPS Consensus Estimate: $2.01 EPS
  • Next Year EPS Consensus Estimate: $1.92 EPS
Additional Links:
Astrazeneca PLC (NYSE:AZN) Chart for Friday, July, 29, 2016